235 related articles for article (PubMed ID: 22911552)
1. Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin.
Gómez-Millán J; Toledo MD; Lupiañez Y; Rueda A; Trigo JM; Sachetti A; Medina JA
Clin Transl Oncol; 2013 Apr; 15(4):321-6. PubMed ID: 22911552
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216).
Adelstein DJ; Moon J; Hanna E; Giri PG; Mills GM; Wolf GT; Urba SG
Head Neck; 2010 Feb; 32(2):221-8. PubMed ID: 19557750
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas.
Medina JA; Rueda A; de Pasos AS; Contreras J; Cobo M; Moreno P; Benavides M; Villanueva A; Alba E
Radiother Oncol; 2006 Apr; 79(1):34-8. PubMed ID: 16626826
[TBL] [Abstract][Full Text] [Related]
4. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.
Gupta P; Dhull AK; Kaushal V
J Cancer Res Ther; 2020; 16(3):478-484. PubMed ID: 32719254
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
7. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
8. Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Lee YJ; Lee CG; Cho BC; Kim GE; Choi HJ; Choi EC; Sohn JH; Kim JH
Head Neck; 2010 Feb; 32(2):235-43. PubMed ID: 19572288
[TBL] [Abstract][Full Text] [Related]
9. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
13. Conventional radiotherapy with concurrent weekly Cisplatin in locally advanced head and neck cancers of squamous cell origin - a single institution experience.
Dimri K; Pandey AK; Trehan R; Rai B; Kumar A
Asian Pac J Cancer Prev; 2013; 14(11):6883-8. PubMed ID: 24377620
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome and morbidity after treatment with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer: results of a multidisciplinary late morbidity clinic.
Rütten H; Pop LA; Janssens GO; Takes RP; Knuijt S; Rooijakkers AF; van den Berg M; Merkx MA; van Herpen CM; Kaanders JH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):923-9. PubMed ID: 21095074
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck.
Homma A; Shirato H; Furuta Y; Nishioka T; Oridate N; Tsuchiya K; Nagahashi T; Aoyama H; Inuyama Y; Fukuda S
Cancer J; 2004; 10(5):326-32. PubMed ID: 15530262
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer.
Pehlivan B; Luthi F; Matzinger O; Betz M; Dragusanu D; Bulling S; Bron L; Pasche P; Seelentag W; Mirimanoff RO; Zouhair A; Ozsahin M
Ann Surg Oncol; 2009 May; 16(5):1337-43. PubMed ID: 19280263
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
Nguyen-Tan PF; Zhang Q; Ang KK; Weber RS; Rosenthal DI; Soulieres D; Kim H; Silverman C; Raben A; Galloway TJ; Fortin A; Gore E; Westra WH; Chung CH; Jordan RC; Gillison ML; List M; Le QT
J Clin Oncol; 2014 Dec; 32(34):3858-66. PubMed ID: 25366680
[TBL] [Abstract][Full Text] [Related]
19. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
20. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
